@evrgn11112231 Yeah that sounds reasonable. And I think gets at one of the bearish argument which is that you’re not seeing the revenue inflection to run rate against it whereas other hyper scalers do see an inflection in cloud backlog
@evrgn11112231 Agree and over the full course of time it does do that, but in the case of a company aggressively ramping capex, depreciation can understate true maintenance for a time because today’s depreciation is still reflective of the smaller asset base.
@evrgn11112231 Maybe these depreciationnumbers account for an appropriate level of maintence capex. I struggle to ballpark these requirements going forward, which is why I ask. I think the bear case implicitly assumes maintence is significantly higher. Appreciate any thoughts.
@evrgn11112231 I share ur directional sentiment & agree w/ big picture point ur making. One Q, isn’t this model irrelevant given the capital intensity u mention, as depreciation likely understates maintence capex, therefore nopat overstates the true cash flow picture?
United Therapeutics meets sp500 qualifications and is on a trajectory to become a very well known company over the next decade. Martine should already be a household name
@ShaleTier7 Off by a country a mile at 45mmBbls/yr. Off by a country mile on $0.80/Bbl (suggests lack of understanding DC water specs). And this is not all you are missing.
@310Value@ShaleTier7 Based on what I have read from @ShaleTier7 he falls into below category. Fails the stupid test. This is super obvious if you read him. Have seen this many times